Nkarta Receives U.S. FDA Orphan Drug Designation for NKX101 for Treatment of Patients with AML
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered...